Chronic pure red cell aplasia (PRCA) is a rare hematologic disorder characterized by a profound failure in the production of red blood cells. It is defined pathologically by severe normocytic, normochromic anemia, a near-complete absence of reticulocytes in the peripheral blood, and a selective depletion of erythroid precursors (erythroblasts) in the bone marrow, while the production of leukocytes and platelets remains normal. The condition can be primary (idiopathic) or secondary, often associated with thymoma, lymphoproliferative disorders, or autoimmune diseases. The mechanism is typically immune-mediated, involving T-cell-mediated suppression of erythropoiesis or autoantibodies (IgG) directed against erythroid progenitor cells or erythropoietin itself.
Distinguish between primary and secondary etiology for chronic pure red cell aplasia.
Example: Patient with established D60.0 chronic pure red cell aplasia secondary to a benign thymoma (D15.0). Bone marrow evaluation demonstrates 0.5 percent erythroid precursors with preserved myeloid and megakaryocytic lineages. Currently transfusion dependent (Z51.3), requiring 2 units of packed red blood cells every 3 weeks. This combination of codes (D60.0 + D15.0) accurately reflects the severity of illness for HCC 46 and supports the medical necessity for surgical consultation.
Billing Focus: Inclusion of the underlying cause (e.g., thymoma or LGL leukemia) as a secondary diagnosis code.
Explicitly document the chronic nature and duration to differentiate from transient erythroblastopenia.
Example: Follow-up for chronic pure red cell aplasia (D60.0) persisting for 14 months. Condition is not transient or related to acute Parvovirus B19 infection (which would map to D60.1). Patient remains refractory to initial corticosteroid therapy. Documentation of chronicity ensures accurate coding for permanent marrow failure syndromes versus temporary viral suppression.
Billing Focus: Usage of the chronic-specific code D60.0 rather than the transient code D60.1.
Document bone marrow biopsy findings including the specific percentage of erythroid precursors.
Example: Clinical diagnosis of D60.0 supported by bone marrow aspiration (38220) and biopsy (38221) showing severe erythroid hypoplasia (less than 1 percent proerythroblasts) with normal cellularity in other lines. Ruling out myelodysplastic syndrome (D46.9) via cytogenetic analysis showing a normal karyotype. This level of detail justifies the level 4 or 5 E/M visit based on the high complexity of data reviewed.
Billing Focus: Correlation between biopsy results and the definitive diagnosis code D60.0.
State transfusion dependence and secondary iron overload if applicable.
Example: Patient with chronic pure red cell aplasia (D60.0) who is now transfusion dependent. Complicated by secondary hemochromatosis (E83.111) due to chronic iron loading from monthly PRBC transfusions. Ferritin level is 2450 ng/mL. Initiating chelation therapy with Deferasirox. Coding both D60.0 and E83.111 captures the true resource intensity of the encounter.
Billing Focus: Reporting complication codes such as iron overload to support medical necessity for chelation.
Record the use of high-risk immunosuppressive medications.
Example: Management of D60.0 chronic pure red cell aplasia currently maintained on Cyclosporine and low-dose Prednisone. Frequent monitoring of renal function and drug levels (80158) required due to medication toxicity. Long-term use of immunosuppressants (Z79.899) documented to support the complexity of the medical decision-making (MDM).
Billing Focus: Inclusion of Z-codes for long-term drug use to provide context for frequent lab monitoring.
Used for routine follow-up of chronic PRCA where treatment adjustments or lab reviews constitute moderate MDM.
Appropriate for complex PRCA cases with multi-system complications (e.g., iron overload) or when discussing high-risk therapies.
Essential procedure to confirm the absence of erythroid precursors and rule out other causes of marrow failure.
Performed alongside biopsy to evaluate individual cell morphology and perform flow cytometry.
Physician review of blood film to confirm normocytic anemia and absence of other cell line abnormalities.
Professional component for reviewing the aspirate smears for erythroid hypoplasia.
Used for the administration of biological agents like Rituximab in refractory PRCA cases.
Standard treatment for maintaining hemoglobin levels in symptomatic chronic PRCA patients.
Primary lab test for monitoring hemoglobin and identifying reticulocytopenia.
Measured to differentiate PRCA from renal-induced anemia; levels are typically very high in PRCA.
Monitoring for iron overload in patients receiving multiple transfusions.
Necessary for adjusting dosages of the primary immunosuppressant used in D60.0 treatment.